Review Article

Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome

Kenneth A. Iczkowski and M. Scott Lucia

Department of Pathology, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA

Correspondence should be addressed to Kenneth A. Iczkowski, kenneth.iczkowski@ucdenver.edu and M. Scott Lucia, scott.lucia@ucdenver.edu

Received 9 March 2011; Accepted 27 March 2011

Academic Editor: R. Montironi

Copyright © 2011 K. A. Iczkowski and M. S. Lucia. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A positive surgical margin at prostatectomy is defined as tumor cells touching the inked edge of the specimen. This finding is reported in 8.8% to 42% of cases (median about 20%) in various studies. It is one of the main determinants of eventual biochemical (PSA) failure, generally associated with a doubled or tripled risk of failure. The effect of a positive margin on outcome can be modified by stage or grade and the length, number and location of positive margins, as well as by technical operative approach and duration of operator experience. This paper tabulates data from the past decade of studies on margin status.

1. Introduction

1.1. Definition of a Positive Surgical Margin (PSM) in Radical Prostatectomy Specimens. As with all surgical specimens resected for cancer, the margins of a prostatectomy specimen are inked, usually using one color dye for the right side and one for the left. It is the pathologist’s task to assess the microscopic slides and determine the proximity of tumor glands or cells to the ink to decide whether there is a definite positive surgical margin (PSM) (Figure 1).

A fundamental question is whether a tumor focus that is close to, but not touching, the resection margin (Figure 2) holds the same implications as a PSM. This question was first answered by Epstein and Sauvageot in 1997, in a study of 101 cases [1]. They found that patients with biochemical progression were no more likely to have tumor close to the margin than those without progression. Emerson et al., confining their study to just 278 margin-negative whole-mount prostate cases, validated that the closest distance between tumor and resection margin was not a significant predictor of PSA recurrence by univariate or multivariate analysis [2]. Thus, it was the consensus of the International Society of Urological Pathology in 2009 not to mention in written reports if tumor merely approaches but does not touch the margin [3]. This contrasts with the practice in other types of specimens such as breast lumpectomy specimens, in which the distance of tumor close to the margin is reported and does matter for outcome.

A PSM is a strong determinant of the probability of biochemical failure and is at least as important as grade, stage, and preoperative serum prostate-specific antigen (PSA). In unselected contemporary studies the PSM rate ranges from 8.8% [4] to 37% [5]. The interobserver reproducibility of designation of a PSM by urologic pathologists, using the definition of tumor on ink, has been shown to be good to excellent. The kappa value is 0.73 for definitive surgical margin status [6]. This supports the validity of many studies in concluding that, compared to negative surgical margin (NSM) status, a PSM correlates with a significant rise in biochemical failure rate. The purpose of this paper is to provide a compendium for urologists and their patients of all that is known about prostate margin status as an outcome predictor.

2. Methods

A review of papers pertaining to prostate margin status and its effect on outcome was undertaken using PubMed searches from 1997 to the present.
Table 1: Comparison of PSM rates by technical approach.

| First author, yr | No. of pts | Cohort yrs | Median f/u, yr | Open PSM rate | Laparoscopic PSM rate | Robotic PSM rate | Failure rate if PSM |
|------------------|------------|------------|----------------|-----------------|-----------------------|------------------|----------------------|
| Williams 2010 [7] | 4240       | 2004–2006  |                | 20.1%           | 17.4%                 | 17.4%            |                      |
| Coelho 2010 [8]   | ≥250††     | 1994–2009  |                | 24.0%           | 21.3%                 | 13.6%            |                      |
| Sciarra 2010 [9]  | 200        | 2003–2007  | 18% anterograde, 14% retrograde | P = .03         | —                     | —                | —                    |
| Williams 2010 [10]| 950        | 2005–2008  | 7.6%           | 13.5%, HR 1.9*, P = .007 | —                     | —                | —                    |
| Coelho 2010 [11]  | 876        | 2008–2009  | —              | —               | pT2, 6.8%, pT3, 34.0% | P < .0001        | —                    |
| Guru 2009 [12]    | 480        | 2005–2008  | —              | —               | 5% apical, 2% versus 8%** | —                | —                    |
| Bong 2009 [13]    | 301        | 1994–2006  | 2.0 24.7% at 1 institution but 4.2% at another | P < .01***       | —                     | —                | 25.6% at 1 institution but 100% at other |
| Hakimi 2009 [14]  | 150        | 2001–2008  | 13.7%          | 12%             | —                     | —                | 6.7% versus 5.3% P = .37 |
| Laurila 2009 [15] | 192        | 2006       | 14%            | —               | —                     | 13%              | P = .5, no diff in apical margin |
| Terakawa 2008 [16]| 137        | 2000–2007  | PSM Not signif.| —               | More multiple PSM, get # | —                | —                    |
| Smith 2007 [17]   | 400        | 2002–2006  | 35%†          | —               | 15%                   | P < .001         | —                    |
| Silva 2007 [18]   | 179        | 1999–2003  | 41.6%          | —               | 24.44%                | P = .023         | —                    |
| Touijer 2007 [19] | 1177       | 2003–2005  | 11.0%; pT2 5.3%, pT3 22.0% | 11.3%; pT2 8.2%, pT3 17.2% | HR 1.2, P = .5 | —                | —                    |

* OR falls to 1.6 if nerve-sparing is eliminated as a variable (P = .05).
** Lower rate achieved by cold incision of the dorsal venous complex before suture ligation.
*** For the same surgeon; but higher average pathologic stage at the first institution.
† But open method was used for more high-risk cases and also cases with a higher preoperative PSA, P = .002.
†† Review of several papers.

3. Results

3.1. Can Prostate Biopsy Results Predict Margin Status? We undertook a study a few years ago to determine the extent to which prostate biopsy results could predict cancer at prostatectomy that is unifocal, unilateral, margin-negative, and of small volume [20]. These four factors are the main criteria for choosing minimally invasive therapies such as targeted focal ablation of the prostate, as alternatives to radical prostatectomy. Unilateral cancer at prostatectomy was predicted by unilateral cancer in the biopsy (OR, 4.30) and unifocal cancer in the biopsy (OR, 2.63). In that study, negative surgical margins were predicted by unilateral cancer in the biopsy (OR 2.53, positive predictive value 82%). Therefore, biopsy findings can strongly predict prostatectomy margin status and other findings.

3.2. Comparison of PSM Rates by Technical Approach (Table 1). In the past decade, nonrobotic or robotic laparoscopic techniques have been increasingly used in place of conventional open radical prostatectomy. The laparoscopic approaches are often considered superior for continence and potency [8, 11, 12, 14, 16]. Most studies involving prostate
Table 2: Comparison of PSM rates by duration of surgical experience.

| First author, yr | Number of cases | Cohort years | Open | Laparoscopic | Robotic |
|------------------|-----------------|--------------|------|--------------|---------|
| Rodriguez 2010 [21] | 400, by intervals of 100 | 2004–2006 | — | For pT2: 28.4%–31.9% to 11.6%–11.5%* | — |
| Yee 2009 [22] | 50, then 250 | 2005–2008 | — | — | — |
| Liss 2008 [23] | 216 | 2003–2007 | — | — | — |
| Eastham 2007 [24] | 2442 | 1983–1990 and 1991–2004 | 18% versus 10%, $P = .001$ | — | — |
| Touijer 2007 [19] | 1177 | 2003–2005 | No decrease over time | Decreased over time, $P = .0002$ | — |

* First 200 cases versus last 200 cases.

Table 3: The effect of margin status on PSA failure rate at 10 years.

| First author, yr | n | Cohort years | PSA fail criterion, ng/mL | % PSM, overall | % biochemical failure rate |
|------------------|---|--------------|---------------------------|----------------|--------------------------|
| Williams 2011 [25] | 158†† | 2005–2009 | — | 13 | 6.9 | $P = .001$ |
| Ahyai 2010 [26] | 932 | 1992–2004 | ≥0.1 | 12.9 | 18 | $P = .0017$ |
| Tsaio 2009 [27] | 100* | 2004–2007 | ≥0.2 | 23 | — | — |
| Sæther 2008 [28] | 219 | 1996–2004 | ≥0.2 | 32.4 | 40 | 18 | $P < .001$, HR 3.21 |
| Pfitzenmaier 2008 [29] | 406 | 1990–2006 | ≥0.2 | 17.2 | 64.3 | 20.5 | $P < .0001$, HR 3.21 |
| Swanson 2007 [30] | 719 | 1985–1995 | ≥0.3 | 15.3 | 63 | 27 | $P < .0001$ |
| Ahyai 2010 [26] | 936 | 1992–2003 | ≥0.4 | 37 | 19 | 7 | $P < .01$ |
| Kausik 2002 [31] | 1202† | 1987–1995 | >0.2 | 42 | 35 | 24 | $P = .0001$ |
| Menon 2010 [32] | 1384* | 2001–2005* | ≥0.2 | 25.1 | — | — | $P < .0001$, HR 2.43 (1.72–3.42) |

* Robotic only.
† Robotic cases only.
†† pT2 cases only.

pathology after laparoscopic approaches have found a PSM rate comparable with that of an open approach [7, 8, 14, 15, 19]. PSM rates were as follow: open, 7.6% [10] to 41.6% [18]; laparoscopic without robot, 11.3% [19] to 21.3% [8]; robotic, 13% [15] to 24.44% [18]. PSM rate for robotic approaches was found to be significantly worse than that for open ones ($P = .007$) in one study [10]; however, two other studies found open approaches superior to the robotic ones [17, 18]. In the study that found the open approach better, the result was confounded by nerve sparing, so robotic prostatectomies showed a nonsignificant trend toward lower PSM for a non-nerve-sparing approach ($P = .09$) [10]. When the anterograde open approach was compared with the retrograde approach, significantly fewer PSMs were found by retrograde approach ($P = .03$) [9].

In a comparison of robotic versus nonrobotic laparoscopic approaches, one study found the robotic method superior [8]. Another found that the outcome was highly stage dependent, with 7% of pT2 patients with biochemical failure as opposed to 34% of pT3 patients [11]. Failure could also depend on number of positive margins [16]. In a study evaluating the robotic approach, a lower PSM rate was achieved by cold incision of the dorsal venous complex before suture ligation [12].

3.3. Comparison of PSM Rates by Duration of Surgical Experience (Table 2). In the above comparison of surgical approaches, it must be noted that the new laparoscopic approaches have a demonstrable learning curve. That is, in three studies conducted in the middle of the 2000–2010 decade, the PSM rate improved after a few years of practice [21–23]. While a significant decrease in PSM rate occurred over time with a laparoscopic approach, PSM held steady for open procedures during the same time period [19]. Even
4 Prostate Cancer

3.4. Margin Status Effect on PSA Failure Rate at 10 Years (Table 3). PSM rates in studies not comparing approaches ranged from 13% [25] to 42% [31] with a median 23% [27]. In the presence of a PSM, the failure rate was either double [28, 30, 32, 34, 40, 42, 43], triple [5, 26, 29, 38] or showed an increase of greater magnitude [4, 39] compared to NSM. Two studies did not specify this [5, 30]. In studies reporting a Hazard Ratio (HR) comparing a PSM to NSM, the HR ranged from 1.3 [46] up to 3.66 [42].

3.5. Tumor Stage (Table 4) or Grade (Table 5) Can Modify the Effect of PSM on PSA Failure Rates, at 10 Years. Nine studies compared PSA failure rates as a function of pathologic stage pT3a and pT3b versus pT2 or of pT3 versus pT2. (The apparent stage sometimes cannot be assessed because of capsular incision [58].) Failure rates with a PSM in stage pT2 ranged from 10.6% [38] to 63% [42], with an HR of 1.7 [4] to 3.81 [34] compared to having an NSM. For stage pT3a, failure rates were 38% [35] to 58% [36], with HR ranging from 1.4 [46] to 3.6 [4] compared to NSM. For stage pT3b, one study reports 71% failure, with HR of 1.4 compared to NSM [35]. Some studies chose to combine both pT3 substages and disclosed failure rates from 57% [37] to 75% [43] and HR of 4.1 [37] to 11.85 [38]. Thus, PSM exerts an effect that is synergistic with increasing stage, although the HR compared to NSM seems fairly constant across stages pT2, pT3a, and pT3b, at about 3 to 4. A study examining the phenomenon of capsular incision, sometimes denoted pT2+, found a 29.3% failure rate versus 7.3% for no incision (P < .0001) [46].

The HR for failure with a PSM seems to increase with increasing Gleason score [4, 35, 42, 44]. In one study [34], however, after controlling for Gleason score, a PSM versus NSM with Gleason ≤7 was significantly predictive of failure, while PSM versus NSM with Gleason ≥8 was not (P = .115). Finally, Ca et al. noted that the Gleason score at the positive margin was predictive of biochemical recurrence [59]. Also, as the Gleason score of the main tumor rose, the concordance with the grade at the margin diminished: 99% for score 6 but 38% for score 9. By multivariate analysis, Gleason score at the margin predicted biochemical failure (P < .05) [59].

3.6. The Effect of PSM on Mortality Rate at 10 Years Is Also Modified by Stage and Grade (Table 6). Three studies addressed the prostate cancer-specific death rate in the presence of a PSM. Two studies, one based on the SEER cancer data registry [45], found a significantly higher death rate at 10 years in the presence of a PSM [34, 45], namely, 0.86% versus 0.33% (P < .001) and 2.6% versus 0.6% which was significant (P = .006). In another study, from the Mayo Clinic registry, a PSM was not a significant predictor of death among 11,729 cases (P = .15), but did predict death in the subset that was stage pT3 [34].

3.7. PSA Failure Rates after a PSM Are Influenced by Length and Number of PSM (Table 7) and by Location of PSM (Table 8). Many pathologists report the length of a PSM. Using categorical PSM length cut-offs between 3 mm and 10 mm, length significantly affected outcome in many [36, 41, 47–49, 58] but not all [50–52] studies. Emerson et al. [53] found a PSM length >3 mm to be a significant outcome predictor by univariate analysis but it fell short of significance by multivariate analysis (P = .076) [53]. Moreover, the length of PSM by frozen section predicted residual tumor in additionally resected neurovascular bundles by multivariate analysis (P < .001) [55].

The number of PSMs probably lacks predictive value. In most studies, number of PSM was not significant for.
Table 4: Modification of PSA failure rates according to stage, at 10 years (unless specified).

| First author, yr | n   | Cohort yr | PSA fail criterion ng/mL | Cohort yrs | PSA failure | % PSM, overall | %P% biochemical failure rate | % biochemical failure rate with PSM by stage | HR pT2 | P value, HR | HR pT3a | P value, HR | Stage pT3b | P value, HR |
|------------------|-----|-----------|--------------------------|------------|-------------|-----------------|-------------------------------|---------------------------------------|------|----------|-------|-----------|----------|------------|
| Williams 2010 [7] | 4240| 2004–2006 | —                        | 19.4       | No f/u      | 14.9            | 42                            | —                                    |      |          |       |           |          |            |
| Ploussard 2010 [34] | 1943| 2000–2008 | >0.2                     |            | 25.6        | 54.2           | 29.9                         | P < .001, HR 2.6                     |      |          |       |           |           |            |
| Budáus 2010 [35]  | 4490| 1992–2008 | ≥0.1                     | 18.9       | —           | 17 versus 5    | HR 2.9                        | 38 versus 26                         |      |          |       |           |           |            |
| Brimo 2010 [36]   | 108†| 1995–2008 | ≥0.2, Inclusion criterion†| —         | —           | —              | —                            | —                                    |      |          |       |           |           |            |
| Hsu 2010 [37]     | 164 | 1977–2004 | ≥0.2                     | 48.2 (all cT3)| —       | —              | 57%                          | HR 4.1, P = .03                      |      |          |       |           |           |            |
| Ficarra 2009 [38] | 322*| 2005–2008 | ≥0.2                     | 29.5       | 6.2         | 18 versus 5    | HR 2.9                        | 26 versus 53                         |      |          |       |           |           |            |
| Kwak 2010 [39]    | 266 | 1995–2007 | ≥0.2                     | 18.5       | 52.6        | 29.3 versus 7.3 | 51 versus 10.5               | P < .0001                            |      |          |       |           |           |            |
| Hashimoto 2008 [40]| 238**| 1985–2005| ≥0.2                     | 34.4       | 38.4        | HR = 1         | —                            | —                                    |      |          |       |           |           |            |
| Chuang 2007 [41]  | 135**| 1993–2004| ≥0.2                     | 28.7       | 3.3         | 28.7 versus 3.3 | P < .0001                    | —                                    |      |          |       |           |           |            |
| Orvieto 2006 [4]  | 996 | 1994–2004 | ≥0.1                     | 8.8 (all); | 35          | 35             | P < .001, HR 3.27             | P < .001, HR = 1.7                   |      |          |       |           |           |            |
| Karakiewicz 2005 [42] | 5831| 1983–2000| ≥0.1–0.4                 | 26.7       | 63.9        | 63 versus 30   | P < .001                    | —                                    |      |          |       |           |           |            |
| Swindle 2005 [43]  | 1369| 1983–2000| ≥0.4                     | 12.9 (all);| 42          | 38.6 versus 19.6| P < .001                    | 74.9% versus 53.8%, P < .001         |      |          |       |           |           |            |

* Robotic only.
** Study used 5-year biochemical recurrence.
† Restricted to GS = 7, stage pT3a, and PSM.
‡ If there is capsular incision, versus no capsular incision.
or posterolateral prostate [41, 47, 49], although one study opposed to a single PSM predicted failure (HR 1.4, \( P \leq .06 \)). In another study, number of PSMs carried only borderline significance when \( \geq 3 \) foci were positive compared to one (HR 1.5–9.5) and not significant for 2 foci compared to one [50]. Emerson et al. found that PSM number predicted failure by univariate analysis (HR 1.63) but lost most of its predictive value when adjusted for Gleason score (HR 2.81) [50]. Emerson et al. noted that the PSM location seemed not to predict failure [53]. However, in two studies, a positive posterolateral margin predicted failure while the apical margin did not [24, 57]. Possibly, residual apical tumor is less viable than residual tumor in the posterolateral region.

4. Conclusion

Prostate margin status is an important determinant of patient outcome after radical prostatectomy. In a 2010 College of American Pathologists survey, this feature was missing from 1% of pathology reports [60], thus the inclusion of this and other essential features is a quality assurance concern.

| First author, yr | Cohort | PSA Fail criterion, ng/mL | % PSM, overall | % biochemical failure rate PSM, NSM | % biochemical failure rate PSM, NSM | Gleason score effect on failure if PSM | Comparisons | P value, HR |
|------------------|--------|---------------------------|----------------|-------------------------------------|-------------------------------------|-------------------------------|-------------|-------------|
| Ploussard 2010 [34] | 1943   | 2000–2008                 | >0.2           | 25.6                                | 54.2                                | 29.9                           | \( P < .001 \) HR 2.6 | \( \leq 7 \) versus \( \geq 8 \) |
| Budäs 2010 [35]   | 4490   | 1992–2008                 | \( \geq 0.1 \)  | 18.9                                | —                                   | —                             | HR 2.81 | HR 6.57 HR 9.86, all \( P < .001 \) |
| Brimo 2010 [36]   | 108†   | 1995–2008                 | \( \geq 0.2 \)  | Inclusion criterion†                 | —                                   | —                             | Score at margin | \( P = .007 \) |
| Alkhateeb 2010 [44] | 11,729† | 1992–2008                 | \( \geq 0.4 \)  | 31.1                                | 56                                  | 77                            | \( P < .0001 \) HR 1.63 | \( \leq 7 \) versus \( \geq 8 \) |
| Orvieto 2006 [4]   | 996    | 1994–2004                 | \( \geq 0.1 \)  | All 8.8; pT2 1.7, pT3a 24.9, pT3b 27.1 | 35                                  | 7.8                           | \( P < .001 \) HR 3.27 | 7 versus \( \geq 8 \), \( P < .001 \), HR 21 |
| Karakiewicz 2005 [42] | 5831 | 1983–2000                 | \( \geq 0.1 \) to \( \geq 0.4 \) | 26.7                                | 63.9                                | 29.9                          | \( P < .001 \) HR 3.66 | \( \leq 7 \), \( P < .0008 \), HR 2.81 |

1 Restricted to GS = 7, stage pT3a, and PSM.
2 Risk groups based on Gleason score and preoperative PSA: low = PSA < 10, Gleason ≤ 6; medium = PSA 10–20 or Gleason 7; high = PSA > 20 or Gleason ≥ 8.

| First author, yr | n | PSA Fail criterion, ng/mL | % PSM, % | Median f/u, yr | PCa death rate if PSM, % | NSM, % | P value, HR | PSM rate or OR by stage pT2 | PSM rate by grade pT3 a-b | Gleason ≥ 7 | P value |
|------------------|---|---------------------------|----------|----------------|--------------------------|--------|-------------|----------------------------|---------------------------|----------------|---------|
| Wright 2010 [45] | 65,633 | —                         | 21.2     | 7              | 0.86                     | 0.33   | \( P < .001 \) | 17.7%                       | 43.8%, \( P < .001 \) | 27.5% versus 18.3% | \( P < .001 \) |
| Boorjian 2010 [34] | 11,729 | \( \geq 0.4 \)            | 31.1     | 8.2            | 4                        | 1      | \( P = .15 \) | HR 1.0                      | HR 2.1, \( P < .0001 \) | —              | —       |
| Ploussard 2010 [34] | 1943 | \( >0.2 \)              | 25.6     | 6.7            | 2.6                      | 0.6    | \( P = .006 \) | 3.7 (1.5–9.5) | 16.0                      | 33.6–40.2 | —       | —       |

Broken down by various sites, a posterolateral PSM predicted failure in most studies [24, 48] but not all [49].
Table 7: Modification of PSA failure rates according to PSM length or number of PSM, at 10 years (unless specified).

| First author, yr | n   | Cohort years | PSA fail criterion ng/mL | Median f/u, yr | %Biochemical failure rate according to length at margin | According to length at margin | According to number of PSM |
|------------------|-----|--------------|--------------------------|---------------|-------------------------------------------------------|-----------------------------|---------------------------|
| Brimo 2010 [36]  | 108 | 1995–2008    | ≥0.2                     | 3.0           | Inclusion criterion —— —                               | P = .004                    | ——                        |
| van Oort 2010 [47] | 174 | 1995–2005    | ≥0.1                     | 3.0           | Inclusion criterion 29 —                               | HR 2.3, P = .022            | >1 versus 1, HR 1.46, P = .24 |
| Lake 2010 [48]   | 1997| 1996–2008    | >0.2                     | 4.1           | 18, 6.7 ext. 62, focal 36 16% | P < .0001                  | ——                        |
| Stephenson 2009 [46] | 7160| 1995–2006   | ≥0.2                     | 3.2           | 21 40                                                   | HR 1.3, P = .004†           | multiple 83%, one 17%, HR 1.4, MVA† P = .002 |
| Shikanov 2009 [49] | 1398| 2003–2008   | ≥0.1                     | 1.0           | 17** —                                                  | P < .0001, HR 4.4           | ——                        |
| Goetzl 2009 [50] | 103 | 1998–2008    | ≥0.2                     | —             | 23.3 —                                                  | ≥6 mm                       | HR 1.7, P = .10           |
| Pfitzenmaier 2008 [29] | 406 | 1990–2006   | ≥0.2                     | 5.2           | 17.2 64.3 20.5                                          | P < .001, HR 3.21           | ≥3 versus 1, HR 1.3, P = .06 Not sig. |
| Marks 2007 [51]  | 158 | 1990–1998    | ≥0.1                     | 4             | — 55 —                                                  | ≥5 mm                       | HR 1.00, P = .26          | ——                        |
| Vis 2006 [52]    | 281 | 1994–1999    | ≥0.1                     | 6.75          | 23.5 33.3 7.9                                          | P < .005                    | ——                        |
| Emerson 2005 [53] | 369 | 1999–2003    | ≥0.1                     | 1.0           | 23 25.6 —                                               | Median 3 mm                 | P = .031 univariate but .076 multivar.†† |
| Sofer 2002 [54]  | 498 | 1995–2008    | ≥0.2                     | 4 yr 5 mo     | 19.7                                                   | HR 2.8, P < .05             | ≥2, versus 1, P = NS      |
| Kausik 2002 [31] | 1202†† | 1987–1995 | >0.2                     | 4.9           | 42 35 24                                               | P = .0001                   | ≥2, 62% versus 1, 65%, P = NS |
| Fromont 2004 [55] | 734 | 1992–1999    | ≥0.2                     | 25            | ——                                                   | ——                          | >2 versus 1, HR 2.19, P not done |

1 Study used 5-year biochemical recurrence.
2 Robotic only.
3 But a predictive model nomogram does not improve accuracy of predicting failure after prostatectomy.
4 Linear extent of positivity was associated with other pathologic variables such as preoperative PSA and tumor volume and not independently predictive when adjusted for Gleason score.
5 Linear extent of positivity was associated with other pathologic variables such as preoperative PSA and tumor volume and not independently predictive when adjusted for Gleason score.
6 Linear extent of positivity was associated with other pathologic variables such as preoperative PSA and tumor volume and not independently predictive when adjusted for Gleason score.
7 Linear extent of positivity was associated with other pathologic variables such as preoperative PSA and tumor volume and not independently predictive when adjusted for Gleason score.
8 Linear extent of positivity was associated with other pathologic variables such as preoperative PSA and tumor volume and not independently predictive when adjusted for Gleason score.
Table 8: Location of PSM and their modification of PSA failure rates, at 10 years (unless specified).

| First author, yr | n  | Cohort years | PSA fail criterion, ng/mL | Median f/u, yr | %PSM, overall | %Biochemical failure rate | Failure according to PSM location | HR and P value | Most common location |
|------------------|----|--------------|---------------------------|----------------|---------------|--------------------------|----------------------------------|----------------|---------------------|
| van Oort 2010 [47] | 174*** | 1995–2005 | ≥0.1 | Inclusion criterion | 29 | — | HR 2.24, ant 35%, apex 33% |
| Lake 2010 [48] | 1997 | 1996–2008 | >0.2 | 4.1 | 18, 6.7 for T2 | Ext. 62 focal 36 | 16 | P < .0001 | — |
| Godoy 2009 [56] | 246*** | 2000–2006 | ≥0.15 | 2.8 | Apical surgical, 3.2, apical soft tissue, 6.6; total 9.8 | — | Apical surgical 48.6%, apical soft tissue, 4.7%*** |
| Stephenson 2009 [46] | 7160 | 1995–2006 | ≥0.2 | 3.2 | 21 | 40 | HR = 2.3 | P < .001 | Apex versus other, HR 1.1, P = .3 |
| Shikanov 2009 [49] | 1398 | 2003–2008 | ≥0.1 | 1.0 | 17** | — | — | P < .0001 | HR 4.4 | Posterolateral P = .7 for fail |
| Pfitzenmaier 2008 [29] | 406 | 1990–2006 | ≥0.2 | 5.2 | 17.2 | 64.3 | 20.5 | P < .001 HR 3.21 | Apex versus nonapex P = .21 |
| Eastham 2007 [24] | 2442 | 1983–2004 | ≥0.2 | 2.9 | 11.2, pT2 7, pT3 22 | 25 | 10 | P = .0005 HR 1.39 | Posterolateral, Posterior HR 2.80, HR 1.96 versus neg, P = .0005 |
| Chuang 2007 [41] | 135*** | 1993–2004 | ≥0.2 | — | — | 28.7*** | 3.3 | P < .0001 | Apex versus other, HR 2.80, HR 1.96 versus neg, P = .0005 |
| Vis 2006 [52] | 281 | 1994–1999 | ≥0.1 | 6.75 | 23.5 | 33.3 | 7.9 | P < .005 | Apex versus other P = .65 |
| First author, yr | n   | Cohort years | PSA fail criterion, ng/mL | Median f/u, yr | %PSM, overall | %Biochemical failure rate | Failure according to PSM location | Most common location |
|-----------------|-----|--------------|---------------------------|----------------|---------------|--------------------------|-----------------------------------|---------------------|
| Emerson 2005 [53] | 369 | 1999–2003 | ≥0.1 | 1.0 | 23 | 25.6 | — | Location, gen'l Ass'n for # of lateral sites: |
| Pettus 2004 [57] | 498 |  | ≥0.2 | 4.4 | 19.7 | | HR 2.9, P < .05, See breakdown | apex 21%, nonapex 26% |
| Kausik 2002 [31] | 1202†† | 1987–1995 | >0.2 | 4.9 | 42 | 35 | 24 | P = .0001 | — |
| Sofer 2002 [54] | 734 | 1992–1999 | ≥0.2 | 25 | — | — | — | — |

*Robotic only.
***Study used 5-year biochemical recurrence.
†pT2 cases only.
††pT3 cases only.
for pathologists. Most urologic pathologists endorse the reporting of the extensiveness of positive margins, expressed as length, number, or radial extent positive for tumor cells; all these measurements have some relevance toward outcome. The presence of a positive margin confers a 2-3-fold increased hazard ratio for biochemical recurrence—modified by stage and tumor grade—and necessitates close clinical followup.

References

[1] J. I. Epstein and J. Sauvageot, “Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression?” Journal of Urology, vol. 157, no. 1, pp. 241–243, 1997.

[2] R. E. Emerson, M. O. Koch, J. K. Daggy, and L. Cheng, “Closest distance between tumor and resection margin in radical prostatectomy specimens: lack of prognostic significance,” American Journal of Surgical Pathology, vol. 29, no. 2, pp. 225–229, 2005.

[3] P. H. Tan, L. Cheng, J. R. Srigley et al., “International society of urological pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 5: surgical margins,” Modern Pathology, vol. 24, no. 1, pp. 48–57, 2011.

[4] M. A. Orvieto, N. F. Alsikafi, A. L. Shalhav et al., “Impact of surgical margin status on long-term cancer control after radical prostatectomy,” BJU International, vol. 98, no. 6, pp. 1199–1203, 2006.

[5] M. A. Simon, S. Kim, and M. S. Soloway, “Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins,” Journal of Urology, vol. 175, no. 1, pp. 140–144, 2006.

[6] A. J. Evans, P. C. Henry, T. H. Van Der Kwast et al., “Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens,” American Journal of Surgical Pathology, vol. 32, no. 10, pp. 1503–1512, 2008.

[7] S. B. Williams, A. V. D’Amico, A. C. Weinberg, X. Gu, S. R. Lipsitz, and J. C. Hu, “Population-based determinants of radical prostatectomy surgical margin positivity,” BJU International, vol. 107, pp. 1734–1740, 2011.

[8] R. F. Coelho, B. Rocco, M. B. Patel et al., “Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers,” Journal of Endourology, vol. 24, no. 12, pp. 2003–2015, 2010.

[9] A. Sciarr, C. Cristini, M. von Heland, S. Salcicca, and V. Gentile, “Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate,” Journal of the Canadian Urological Association, vol. 4, no. 3, pp. 192–198, 2010.

[10] S. B. Williams, M. H. Chen, A. V. D’Amico et al., “Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s),” Urology, vol. 76, pp. 1097–1101, 2010.

[11] R. F. Coelho, S. Chauhan, M. A. Orvieto, K. J. Palmer, B. Rocco, and V. R. Patel, “Predictive factors for positive surgical margins and their locations after robot-assisted laparoscopic radical prostatectomy,” European Urology, vol. 57, no. 6, pp. 1022–1029, 2010.
organ-confined prostate cancer,” BJU International, vol. 106, no. 4, pp. 478–483, 2010.

[27] A. K. Tsao, M. D. Smaldone, T. D. Averch, and S. V. Jackman, “Robot-assisted laparoscopic prostatectomy: the first 100 patients-improving patient safety and outcomes,” Journal of Endourology, vol. 23, no. 3, pp. 481–484, 2009.

[28] T. Sather, L. T. Sorøien, T. Viset, S. Lydersen, and A. Angelsen, “Are positive surgical margins in radical prostatectomy specimens an independent prognostic marker?” Scandinavian Journal of Urology and Nephrology, vol. 42, no. 6, pp. 514–521, 2008.

[29] J. Pitzenmaier, S. Pal hernik, T. Tremmel, A. Haferkamp, S. Buse, and M. Hohenfellner, “Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?” BJU International, vol. 102, no. 10, pp. 1413–1418, 2008.

[30] G. P. Swanson, M. Riggs, and M. Hermans, “Pathologic findings at radical prostatectomy: risk factors for failure and death,” Urologic Oncology, vol. 25, no. 2, pp. 110–114, 2007.

[31] S. J. Kausik, M. L. Blute, T. J. Sebo et al., “Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy,” Cancer, vol. 95, no. 6, pp. 1215–1219, 2002.

[32] M. Menon, M. Bhandari, N. Gupta et al., “Biochemical recurrence following robot-assisted radical prostatectomy: analysis of 3384 patients with a median 5-year follow-up,” European Urology, vol. 58, no. 6, pp. 838–846, 2010.

[33] J. A. Eastham, M. W. Kattan, E. Riedel et al., “Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens,” Journal of Urology, vol. 170, no. 6, pp. 2292–2295, 2003.

[34] G. Ploussard, M. A. Agamy, and O. Alenda, “Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients,” BJU International, vol. 107, pp. 1748–1754, 2011.

[35] L. Budäus, H. Isbarn, C. Eichelberg et al., “Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage,” Journal of Urology, vol. 184, no. 4, pp. 1341–1346, 2010.

[36] F. Brimo, A. W. Partin, and J. I. Epstein, “Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis,” Urology, vol. 76, no. 5, pp. 1206–1209, 2010.

[37] C. Y. Hsu, M. F. Wildhagen, H. Van Poppel, and C. H. Bangma, “Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy,” BJU International, vol. 105, no. 11, pp. 1536–1540, 2010.

[38] V. Ficarra, G. Novara, S. Secco et al., “Predictors of positive surgical margins after laparoscopic robot assisted radical prostatectomy,” Journal of Urology, vol. 182, no. 6, pp. 2682–2688, 2009.

[39] K. W. Kwak, H. M. Lee, and H. Y. Choi, “Impact of capsular incision on biochemical recurrence after radical perineal prostatectomy,” Prostate Cancer and Prostatic Diseases, vol. 13, no. 1, pp. 28–33, 2010.

[40] K. Hashimoto, N. Masumori, F. Takei et al., “Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy,” Japanese Journal of Clinical Oncology, vol. 38, no. 1, pp. 31–35, 2008.

[41] A. Y. Chuang, M. E. Nielsen, D. J. Hernandez, P. C. Walsh, and J. I. Epstein, “The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy,” Journal of Urology, vol. 178, no. 4, pp. 1306–1310, 2007.

[42] P. I. Karakiewicz, J. A. Eastham, M. Graefen et al., “Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients,” Urology, vol. 66, no. 6, pp. 1245–1250, 2005.

[43] P. Swindle, J. A. Eastham, M. Ohori et al., “Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens,” Journal of Urology, vol. 174, no. 3, pp. 903–907, 2005.

[44] S. Alkhateeb, S. Alibhai, N. Fleshner et al., “Impact of positive surgical margins after radical prostatectomy differs by disease risk group,” Journal of Urology, vol. 183, no. 1, pp. 145–150, 2010.

[45] J. L. Wright, B. L. Dalkin, L. D. True et al., “Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality,” Journal of Urology, vol. 183, no. 6, pp. 2213–2218, 2010.

[46] A. J. Stephenson, D. P. Wood, M. W. Kattan et al., “Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy,” Journal of Urology, vol. 182, no. 4, pp. 1357–1363, 2009.

[47] I. M. Van Oort, H. M. Bruins, L. A. L. M. Kiemeney, B. C. Knipscheer, J. A. Witjes, and C. A. Hulsbergen-Van De Kaa, “The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy,” Histopathology, vol. 56, no. 4, pp. 464–471, 2010.

[48] A. M. Lake, C. He, and D. P. Wood Jr., “Focal positive surgical margins decrease disease-free survival after radical prostatectomy even in organ-confined disease,” Urology, vol. 76, pp. 1212–1216, 2010.

[49] S. Shikanov, J. Song, C. Royce et al., “Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence,” Journal of Urology, vol. 182, no. 1, pp. 139–144, 2009.

[50] M. A. Goetzl, R. Krebill, T. L. Griebling, and J. B. Thrasher, “Predictors of positive surgical margins after radical perineal prostatectomy,” The Canadian Journal of Urology, vol. 16, no. 2, pp. 4553–4557, 2009.

[51] R. A. Marks, M. O. Koch, A. Lopez-Beltran, R. Montironi, B. E. Juliar, and L. Cheng, “The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens,” Human Pathology, vol. 38, no. 8, pp. 1207–1211, 2007.

[52] A. N. Vis, F. H. Schröder, and T. H. van der Kwast, “The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer,” European Urology, vol. 50, no. 2, pp. 258–265, 2006.

[53] R. E. Emerson, M. O. Koch, T. D. Jones, J. K. Daggy, B. E. Juliar, and L. Cheng, “The influence of extent of surgical margin positivity on prostate specific antigen recurrence,” Journal of Clinical Pathology, vol. 58, no. 10, pp. 1028–1032, 2005.

[54] M. Sofer, K. L. Hamilton-Nelson, F. Civantos, and M. S. Soloway, “Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression,” Journal of Urology, vol. 174, no. 3, pp. 903–907, 2005.

[55] G. Fromont, C. Thostenson, F. Rozet, D. Prapotnick, P. Valdivie, and G. Vallancien, “Impact of margin size on the incidence of local residual tumor after laparoscopic radical
[56] G. Godoy, B. U. Tareen, and H. Lepor, "Is the apical soft tissue margin a better predictor of biochemical recurrence than the surgical specimen?" Urologic Oncology. In press.

[57] J. A. Pettus, C. J. Weight, C. J. Thompson, R. G. Middleton, and R. A. Stephenson, "Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location," Journal of Urology, vol. 172, no. 1, pp. 129–132, 2004.

[58] A. Y. Chuang and J. I. Epstein, "Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: histologic features and pitfalls," American Journal of Surgical Pathology, vol. 32, no. 8, pp. 1201–1206, 2008.

[59] D. Cao, A. S. Kibel, F. Gao, Y. Tao, and P. A. Humphrey, “The gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence,” American Journal of Surgical Pathology, vol. 34, no. 7, pp. 994–1001, 2010.

[60] M. O. Idowu, L. G. Bekeris, S. Raab, S. G. Ruby, and R. E. Nakleh, “Adequacy of surgical pathology reporting of cancer: a college of American pathologists q-probes study of 86 institutions,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 7, pp. 969–974, 2010.